Merck May Be Positioned For First Approval Of A Protease Inhibitor In HCV
The pharma announced Jan. 6 that boceprevir has been accepted for priority review by FDA, making an early-May action date likely.
The pharma announced Jan. 6 that boceprevir has been accepted for priority review by FDA, making an early-May action date likely.